Financial statements Evomed
Cash flow statement of Evomed
Company age:
Age:
23 y. 4 d.
Share capital:
Share capital:
60 000 PLN
Cash inflows of EVOMED
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Net cash from operating expenses | 5 150 922,60 | 4 928 511,54 | 4 653 507,88 | 5 052 376,13 | 5 827 143,17 | 7 319 658,74 |
| Net cash flow from investing activities | -886 646,24 | -1 297 854,36 | -1 401 989,99 | -2 408 981,07 | -1 605 557,80 | -13 301 591,66 |
| Net cash flow from financial activities | -4 076 949,88 | -1 457 842,83 | -2 985 250,22 | -766 892,31 | -597 912,66 | -1 521 953,47 |
| Total net cash flow | 187 326,48 | 2 172 814,35 | 266 267,67 | 1 876 502,75 | 3 623 672,71 | -7 503 886,39 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.